Overview
- A Washington University study published in JAMA on Nov. 13 found that a blood tau fragment called eMTBR‑tau243 was higher in people with autopsy‑confirmed advanced chronic traumatic encephalopathy and tracked with disease severity.
- The eMTBR‑tau243 signal distinguished advanced CTE from healthy controls but did not reliably detect early‑stage CTE and was lower than levels seen in Alzheimer’s disease.
- Because eMTBR‑tau243 also rises in Alzheimer’s and other tauopathies the marker cannot by itself tell CTE apart when the diseases coexist, so researchers say it will not be a standalone diagnostic test.
- Separately, a scalable immunoassay for eMTBR‑tau reproduced mass‑spectrometry performance in 728 people and a Mayo Clinic JAMA Neurology paper showed plasma p‑tau217 combined with age, sex and APOE ε4 can estimate five‑ and ten‑year risk of cognitive impairment.
- Experts caution that larger, more diverse prospective studies and head‑to‑head comparisons with imaging and neuropathology are needed before these tests are used clinically, though validated assays could speed trial enrollment and give at‑risk people clearer guidance about future care.